Results from a phase I study of andecaliximab in combination with FOLFIRI and bevacizumab in patients with second line metastatic colorectal cancer.

被引：0
|
作者：
Wainberg, Zev A.
Bendell, Johanna C.
Lenz, Heinz-Josef
Baron, Ari David
Berlin, Jordan
Bessudo, Alberto
Bruetman, Daniel
Chung, Ki Y.
Park, Haeseong
Patel, Manish R.
Adewoye, Adeboye H.
Liu, JieJane
Patel, Ravindranath
Shah, Manish A.
机构：
[1] UCLA, David Geffen Sch Med, Los Angeles, CA USA
[2] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA
[3] USC, Keck Sch Med, Los Angeles, CA USA
[4] Calif Pacif Med Ctr Res Inst, San Francisco, CA USA
[5] Vanderbilt Univ, Ingram Canc Ctr, Nashville, TN USA
[6] Calif Canc Care Associates Res & Excellence, Encinitas, CA USA
[7] Goshen Ctr Canc Care, Goshen, IN USA
[8] Greenville Hlth Syst Canc Inst, Greenville, SC USA
[9] Washington Univ, Sch Med, St Louis, MO USA
[10] Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA
[11] Gilead Sci Inc, Foster City, CA USA
[12] Comprehens Blood & Canc Ctr, Bakersfield, CA USA
[13] New York Presbyterian Hosp, Weill Cornell Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.3578
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3578
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Results of a phase I study of andecaliximab in combination with mFOLFOX6 and bevacizumab in patients with previously untreated metastatic colorectal cancer
    Lenz, H-J.
    Park, H.
    Shah, M. A.
    Berlin, J. D.
    Bruetman, D.
    Chaves, J.
    Gordon, M.
    Patel, R.
    Starodub, A.
    Liu, J.
    Brachmann, C. Baker
    Bhargava, P.
    Wainberg, Z. A.
    Bendell, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [2] Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
    Hiroya Taniguchi
    Toshiki Masuishi
    Akihito Kawazoe
    Kei Muro
    Shigenori Kadowaki
    Hideaki Bando
    Shuichi Iino
    Rie Kageyama
    Takayuki Yoshino
    International Journal of Clinical Oncology, 2021, 26 : 2017 - 2024
  • [3] Phase I study of napabucasin in combination with FOLFIRI plus bevacizumab in Japanese patients with metastatic colorectal cancer
    Taniguchi, Hiroya
    Masuishi, Toshiki
    Kawazoe, Akihito
    Muro, Kei
    Kadowaki, Shigenori
    Bando, Hideaki
    Iino, Shuichi
    Kageyama, Rie
    Yoshino, Takayuki
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (11) : 2017 - 2024
  • [4] Aflibercept or bevacizumab in combination with FOLFIRI as second-line treatment of mRAS metastatic colorectal cancer patients: the ARBITRATION study protocol
    Ottaiano, Alessandro
    Scala, Stefania
    Santorsola, Mariachiara
    Trotta, Anna Maria
    D'Alterio, Crescenzo
    Portella, Luigi
    Clemente, Ottavia
    Nappi, Anna
    Zanaletti, Nicoletta
    De Stefano, Alfonso
    Avallone, Antonio
    Granata, Vincenza
    Notariello, Carmen
    Luce, Amalia
    Lombardi, Angela
    Picone, Carmine
    Petrillo, Antonella
    Perri, Francesco
    Tatangelo, Fabiana
    Di Mauro, Annabella
    Albino, Vittorio
    Izzo, Francesco
    Rega, Daniela
    Pace, Ugo
    Di Marzo, Massimiliano
    Chiodini, Paolo
    De Feo, Gianfranco
    Del Prete, Paola
    Botti, Gerardo
    Delrio, Paolo
    Caraglia, Michele
    Nasti, Guglielmo
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [5] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [6] A phase I study of sunitinib in combination with FOLFIRI in patients with untreated metastatic colorectal cancer
    Starling, N.
    Vazquez-Mazon, F.
    Cunningham, D.
    Chau, I.
    Tabernero, J.
    Ramos, F. J.
    Iveson, T. J.
    Saunders, M. P.
    Aranda, E.
    Countouriotis, A. M.
    Ruiz-Garcia, A.
    Wei, G.
    Tursi, J. M.
    Guillen-Ponce, C.
    Carrato, A.
    ANNALS OF ONCOLOGY, 2012, 23 (01) : 119 - U110
  • [7] Results from a phase I study of andecaliximab in combination with paclitaxel in patients with previously untreated metastatic breast cancer
    Hamilton, Erika Paige
    Bessudo, Alberto
    Bruetman, Daniel
    Gordon, Michael S.
    Patel, Ravindranath
    Adewoye, Adeboye H.
    Liu, JieJane
    Starodub, Alexander
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Phase I study of gefitinib in combination with FOLFIRI as 2nd-/3rd-line treatment in patients with metastatic colorectal cancer.
    Hochhaus, A
    Hofheinz, R
    Heike, M
    Schlag, R
    Gahlemann, CG
    Kubicka, S
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 289S - 289S
  • [9] A randomized Phase 1b study of IGM-8444 in combination with FOLFIRI plus bevacizumab compared to FOLFIRI plus bevacizumab alone in second line metastatic colorectal cancer
    Ulahannan, Susanna
    Pelster, Meredith
    LoRusso, Patricia
    Falchook, Gerald
    Wang, Judy
    Barve, Minal
    Grewal, Jaspreet
    Chow, Warren
    Henry, Jason
    Cecchini, Michael
    Subbiah, Vivek
    Leabman, Maya
    Hernandez, Genevive
    Li, Yao
    Sinclair, Angus
    Wang, Beatrice
    Kotturi, Maya
    Humke, Eric
    Ahern, Sean
    Ennis, Leslie
    Caruano, Melaine
    Agrawal, Sapeck
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [10] Onvansertib in Combination with FOLFIRI and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Phase Ib Clinical Study
    Ahn, Daniel H.
    Barzi, Afsaneh
    Ridinger, Maya
    Samuelsz, Errin
    Subramanian, Ramanand A.
    Croucher, Peter J. P.
    Smeal, Tod
    Kabbinavar, Fairooz F.
    Lenz, Heinz-Josef
    CLINICAL CANCER RESEARCH, 2024, 30 (10) : 2039 - 2047
12345